Viewing Study NCT01141751


Ignite Creation Date: 2025-12-24 @ 11:51 PM
Ignite Modification Date: 2026-02-07 @ 2:58 PM
Study NCT ID: NCT01141751
Status: COMPLETED
Last Update Posted: 2014-07-14
First Post: 2010-06-09
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
Sponsor: Merck KGaA, Darmstadt, Germany
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Sclerosis, Relapsing-Remitting View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Multiple sclerosis View
None Expanded Disability Status Scale View
None Multiple Sclerosis, Relapsing-Remitting; Rebif View
None Beta-1, interferon View